Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab tirumotecan + immune checkpoint inhibitor
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Sacituzumab tirumotecan (MK-2870/SKB264) is a trophoblast cell-surface antigen 2 (Trop-2)-directed antibody-drug conjugate (ADC) consisting of a humanized anti-Trop-2 monoclonal antibody conjugated to a topoisomerase I inhibitor payload (tirumotecan, a camptothecin derivative). This combination therapy pairs the ADC with an immune checkpoint inhibitor (ICI), typically targeting the PD-1/PD-L1 pathway, to enhance anti-tumor activity through synergistic mechanisms: the ADC induces direct tumor cell death and potentially promotes immunogenic cell death, while the ICI reinvigorates the T-cell-mediated immune response. This specific combination is being investigated in a Phase 2 clinical trial for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) who have progressed on prior therapies.
- Other names
- sacituzumab tirumotecan plus immune checkpoint inhibitor
02
Targets
TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on sacituzumab tirumotecan + immune checkpoint inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab tirumotecan + immune checkpoint inhibitor.